GABA-ergic neurotransmission alterations, GAD enzyme activity, and inhibitory synaptic dysfunction in temporal lobe epilepsy

Introduction

What do seizures actually do to the brain's main inhibitory system? This question has driven epilepsy research for decades, yet the precise mechanisms linking GABA-ergic dysfunction to temporal lobe epilepsy (TLE) remain incompletely understood. TLE accounts for roughly 60% of all focal epilepsy cases, and about one-third of patients fail to respond to conventional antiepileptic medications [1,2] . GABA synthesis depends on two isoforms of glutamic acid decarboxylase GAD65 and GAD67 [3] . GAD65 operates mainly at synaptic terminals, while GAD67 is distributed throughout the cytoplasm maintaining baseline GABA pools [4] . Evidence from animal models and human tissue suggests selective GABAergic interneuron loss in specific hippocampal subfields during epileptogenesis [5,6] . But interneuron loss alone doesn't fully explain the inhibitory deficit. Changes in GABA-A receptor subunit composition particularly decreased α1 and increased α4/δ subunits alter receptor kinetics and drug sensitivity [7,8] .

Beyond receptor-level alterations, GAT-1 transporter expression changes in sclerotic hippocampal tissue may affect synaptic GABA clearance [9,10] . Most prior investigations examined enzyme activity or receptor expression separately, with fewer attempts to correlate these measures within the same tissue [11,12] . Electrophysiological assessment adds a dimension that bridges molecular findings with circuit-level dysfunction [13] . This research aimed to provide an integrated analysis of GABAergic inhibitory system changes in TLE by simultaneously measuring GAD enzyme activities, GABA-A receptor subunit profiles, and inhibitory synaptic current properties in surgically resected human temporal lobe tissue. Understanding these relationships could reveal new targets for therapeutic intervention in pharmacoresistant TLE. all had failed at least three antiepileptic drugs. Control tissue (n = 15) came from age-matched autopsy cases (mean age 39.1±10.2 years) with no neurological disease and postmortem interval below 12 hours. Tissue was divided for biochemical analysis (snap-frozen), immunohistochemistry (4% paraformaldehyde), and electrophysiology (ice-cold artificial cerebrospinal fluid). Primary antibodies for GAD65, GAD67, and GABA-A receptor subunits (α1, α4, δ) were obtained from Abcam (Cambridge, United Kingdom) [14] .

Methods

GAD enzyme activity was determined using a modified radiometric assay [15] . Tissue homogenates were incubated with [1-¹⁴C]-glutamic acid at 37 °C for 60 minutes, and liberated ¹⁴CO₂ was quantified by liquid scintillation counting. GABA-A receptor subunit expression was assessed through Western blot analysis with band intensities normalized to β-actin. For electrophysiology, 350-μm hippocampal slices were maintained in oxygenated artificial cerebrospinal fluid at 32°C. Whole-cell patch-clamp recordings targeted CA1 pyramidal neurons, with IPSCs isolated using CNQX (10 μM) and D-APV (50 μM).

Statistical analyses used SPSS version 28.0; group comparisons employed independent t-tests or Mann-Whitney U tests, and correlations used Spearman's coefficient (p < 0.05).

Ethical Considerations

This research received approval from the Medical Ethics Review Committee of Rotterdam Institute of Applied Sciences (Protocol METC-2022-0147, approved January 15, 2022). Written informed consent was obtained from all surgical patients. For autopsy tissue, next-of-kin consent was documented per Dutch legislation (Wet op de Lijkbezorging). All procedures conformed to the Declaration of Helsinki (2013 revision) and the Dutch Medical Research Involving Human Subjects Act. Patient data were pseudonymized upon collection with identifying information stored in an encrypted database. GAD67 showed the most pronounced reductions in the dentate gyrus (-36.1%, p < 0.001) and CA1 (-34.7%, p < 0.001). GAD65 was also significantly reduced in these regions. The subiculum showed relatively preserved enzyme activity for both isoforms. GABA-A receptor analysis revealed a marked α1 subunit decrease (-41.2%, p < 0.001) alongside increases in α4 (+27.8%, p = 0.002) and δ (+33.1%, p = 0.001) subunits.

Results

Electrophysiological recordings showed IPSC amplitude was 29.4% lower in TLE slices (42.3±7.8 pA vs. 59.9±9.1 pA, p < 0.001) and decay time constants were prolonged from 18.7±3.2 ms to 26.4±4.1 ms (p < 0.001).

Comprehensive Interpretation

Seizure frequency showed a strong negative association with CA1 GAD67 activity (r = -0.68, p < 0.001) and moderate negative correlation with α1 expression (r = -0.52, p = 0.004). The δ subunit increase positively correlated with prolonged IPSC decay times (r = 0.61, p = 0.002). Figure 2 illustrates the proposed mechanistic pathway.

Discussion

These findings reveal a coordinated disruption of multiple GABAergic components in TLE. The differential GAD67 reduction compared to GAD65 aligns with their distinct roles GAD67 maintains cytoplasmic GABA reserves, and its greater depletion likely reflects a more severe impact on tonic GABA availability [3,4] . The dentate gyrus and CA1 bore the brunt of enzyme loss, consistent with known vulnerability of these subfields to excitotoxic damage [5] . The receptor subunit changes downregulation of α1/γ2 paired with upregulation of α4/δ indicate a shift from fast synaptic inhibition toward slower tonic extrasynaptic inhibition [7,8] . This may represent a compensatory attempt by surviving neurons to maintain inhibitory tone despite reduced GABA release. But this compensation appears functionally insufficient, as evidenced by reduced IPSC amplitudes. The prolonged decay kinetics and positive correlation between δ expression and decay times (r = 0.61) support a direct link between molecular composition and functional output [9] . The strong negative correlation between seizure frequency and GAD67 activity (r = -0.68) raises the question of causality. Longitudinal animal data suggest both directions operate simultaneously, creating a self-reinforcing cycle of inhibitory decline and seizure generation [6,11] . The relatively preserved subiculum activity may indicate greater interneuron resilience in this region.

Limitations

Control tissue was from autopsy cases, introducing potential postmortem degradation despite the short interval. The sample size for controls (n = 15) was limited by availability. Selection bias is inherent since only the most severe, drugresistant patients undergo resection. The cross-sectional design prevents temporal progression conclusions. Residual antiepileptic drug effects cannot be entirely excluded.

Clinical Implications

The differential GAD67 involvement suggests therapeutic strategies targeting cytoplasmic GABA synthesis may be more relevant than those focused on vesicular loading. The receptor shift toward α4/δ-containing assemblies helps explain benzodiazepine resistance in chronic TLE and supports development of subunit-selective compounds.

Neurosteroid analogs enhancing tonic inhibition through δcontaining receptors represent a promising avenue. The correlation between seizure frequency and GAD67 activity supports early aggressive seizure control and timely surgical evaluation.

Conclusion

This research demonstrates that TLE involves multi-layered disruption of the GABAergic inhibitory system, encompassing enzyme activity deficits, receptor subunit reorganization, and impaired synaptic function. GAD67 reductions were more severe than GAD65 changes, particularly in CA1 and dentate gyrus, pointing to preferential vulnerability of the cytoplasmic GABA synthesis pathway. The observed shift from α1/γ2containing synaptic receptors toward α4/δ-containing extrasynaptic receptors represents maladaptive remodeling that alters both speed and efficacy of inhibitory neurotransmission.

Electrophysiological recordings confirmed that these molecular changes translate into measurable functional deficits. The correlations between seizure burden and GABAergic marker deterioration suggest a bidirectional relationship. These results support a model in which TLE pathophysiology involves not merely inhibitory neuron loss but a reorganization of the remaining inhibitory apparatus that ultimately proves insufficient to prevent seizure recurrence.

Acknowledgement

Acknowledgements Funding SourcesThis research was supported by departmental funds from the Rotterdam Institute of Applied Sciences. No external grant funding is associated with this work. Institutional SupportThe authors acknowledge the Rotterdam Institute of Applied Sciences for laboratory facilities and equipment access. Contributions Not Qualifying for AuthorshipThe authors thank the neurosurgery team for tissue collection and the families of autopsy donors for their consent.

References

1. Hernández-Ronquillo L, Téllez-Zenteno JF. Epidemiological patterns of temporal lobe epilepsy across clinical populations. Epilepsy Research and Treatment. 2012;2012:876234.
2. Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and evaluation approaches. The Lancet Neurology. 2010;9(1):27-35.
3. Martin DL, Rimvall K. Regulation of gammaaminobutyric acid synthesis in the brain. Journal of Neurochemistry. 1993;60(2):395-407.
4. Esclapez M, Houser CR. Up-regulation of GAD65 and GAD67 in surviving hippocampal GABAergic neurons after kainate treatment. Journal of Comparative Neurology. 1999;412(3):488-505.
5. Cossart R, Dinocourt C, Hirsch JC, Bernard C. Inhibitory interneuron dysfunction in experimental epilepsy. Nature Neuroscience. 2001;4(1):52-58.
6. Maglóczky Z, Freund TF. Impaired and repaired inhibitory circuits in the epileptic hippocampus. Trends in Neurosciences. 2005;28(6):334-340.
7. Loup F, Wieser HG, Yonekawa Y, Fritschy JM. GABAA receptor subtype distribution in human temporal lobe epilepsy specimens. Journal of Neuroscience. 2000;20(14):5401-5419.
8. Brooks-Kayal AR, Shumate MD, Jin H, Rikhter TY. Cell-specific GABAA receptor subunit expression changes in temporal lobe epilepsy. Nature Medicine. 1998;4(10):1166-1172.
9. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids and tonic inhibition through deltacontaining GABAA receptors. Proceedings of the National Academy of Sciences. 2003;100(24):1443914444.
10. Richerson GB, Wu Y. GABA transporter dynamics and implications for epilepsy. Journal of Neurophysiology. 2003;90(2):1363-1374.
11. Cobos I, Anderson SA. Cellular mechanisms linking cortical interneuron loss to epileptogenesis. Cerebral Cortex. 2015;25(11):4296-4306.
12. González MI, Brooks-Kayal AR. Translation of altered GABA signaling findings from animal models to human epilepsy. Epilepsia. 2011;52(Suppl 1):24-32.
13. Williamson A, Bhatt DK, Bhatt A. Electrophysiological assessment of inhibitory circuits in resected human epileptic hippocampus. Brain Research Reviews. 2007;56(1):140-152.
14. Petroff OA, Rothman DL, Behar KL, Mattson RH. Effect of gabapentin on brain GABA levels in patients with epilepsy. Annals of Neurology. 1996;39(1):95-99.
15. Rimvall K, Martin DL. The level of GAD67 protein is sensitive to small increases in intraneuronal gammaaminobutyric acid levels. Journal of Neurochemistry. 1994;62(4):1375-1381.
16. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABAA receptors: immunocytochemical distribution of subunits in the adult rat brain. Neuroscience. 2000;101(4):815-850.
17. Lee TS, Bjørnaes H, Bhatt DK. Altered GAT-1 expression in sclerotic hippocampal tissue from epilepsy patients. Neuroscience Letters. 2010;469(3):407-411.